Shattuck Labs STTK 深 沪
已收盘 12-12 16:00:00 美东时间
3.10
-0.130
-4.02%
华盛通- 最 高3.27
- 今 开3.22
- 成交量 15.99万股
- 最 低 3.07
- 昨 收 3.23
- 总市值 1.96亿
- 52周最高 3.38
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.6922
- 委 比 79.00%
- 总股本 6327.98万
- 历史最高 60.516
- 量 比 0.27
- 振 幅 6.19%
- 历史最低 0.6922
- 每 手 1
- 风险率 0.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy
HC Wainwright upgrades Shattuck Labs on confidence in SL-325, a DR3 antibody aiming for stronger, durable IBD treatment amid TL1A concerns.
12-02 05:33
HC Wainwright & Co. Upgrades Shattuck Labs to Buy, Announces $6 Price Target
HC Wainwright & Co. analyst Joseph Pantginis upgrades Shattuck Labs (NASDAQ:STTK) from Neutral to Buy and announces $6 price target.
12-01 20:18
Shattuck Labs to Participate in Upcoming December Investor Conferences
Shattuck Labs, Inc. announced that its management will participate in two investor conferences in December 2025. The first is the Piper Sandler 37th Annual Healthcare Conference on Dec 2, featuring a presentation by CEO Taylor Schreiber, available via webcast. The second is the Evercore ISI 8th Annual HealthCONx Conference, with a fireside chat on Dec 4. Both events include one-on-one meetings. The company is developing SL-325, a novel DR3 blocki...
11-20 13:00
Shattuck Labs Q3 EPS $(0.14), Inline, Sales $1.000M Down From $2.997M YoY, Cash Balance Of $86.1M Expected To Provide Cash Runway Into 2029
As of September 30, 2025, cash and cash equivalents and short-term investments were approximately $86.1 million. Shattuck's current cash and cash equivalents and short-term investments, assuming the full exercise of the
11-07 05:59
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs reported financial results for Q3 2025, including a net loss of $10.1 million, and highlighted business progress such as completing Phase 1 dosing for SL-325, closing a $103 million private placement, and appointments to its Board of Directors. The company expects its current cash to fund operations into 2029.
11-06 21:30
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
10-21 05:08
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
Shattuck Labs announced that its management will participate in a panel discussion reviewing key insights from the 2025 United European Gastroenterology Week Conference. The session, titled "Wedbush UEGW Conference 2025 Rewind," will be held on October 8, 2025, from 10:00am to 12:00pm EST, and will feature experts including Shattuck’s CEO, Taylor Schreiber, M.D., Ph.D. Shattuck is developing SL-325, a potential first-in-class DR3 blocking antibod...
10-02 11:51
Wedbush Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4
Wedbush analyst David Nierengarten initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Outperform rating and announces Price Target of $4.
09-08 21:07
